Fubotv earnings beat by $0.10, revenue topped estimates
Mangoceuticals , Inc., a Texas-based health services company with a market capitalization of $11.11 million, has reported the conversion of Series B Convertible Preferred Stock into common shares. According to InvestingPro data, the company maintains impressive gross profit margins of 61.7% despite showing an overall weak financial health score. On March 28, 2025, three separate conversions took place, resulting in a total issuance of 287,467 new common shares. This transaction was conducted under the exemption provided by Section 3(a)(9) of the Securities Act of 1933, which allows for such exchanges without registration if no commission is paid for the solicitation.
The conversions included 260 shares of Series B Convertible Preferred Stock with an aggregate stated value of $286,000, which were converted into 190,667 common shares. Additionally, 74 shares of preferred stock valued at $81,400 were exchanged for 54,267 common shares, and 58 shares with a stated value of $63,800 were converted into 42,533 common shares. All conversions were based on the current conversion price of $1.50 per share. The stock has experienced significant volatility, with InvestingPro analysis showing a 48% decline over the past six months.
Mangoceuticals, which operates under the trading symbol (NASDAQ:MGRX), is classified as an emerging growth company. The conversions are part of the company’s financial maneuvers and reflect its capital structure strategy. The company’s CEO, Jacob D. Cohen, signed off on the SEC filing dated April 2, 2025, confirming the conversions.
The conversions are likely to impact the company’s share structure, affecting both the equity value and the distribution of ownership. Current and potential investors may consider the dilutive effect of such conversions when analyzing the company’s stock value. With the company’s next earnings report scheduled for April 8, 2025, and current Fair Value calculations from InvestingPro suggesting the stock is slightly undervalued, investors should carefully monitor these developments. InvestingPro subscribers have access to 13 additional investment tips and comprehensive financial metrics for deeper analysis.
This report is based on a press release statement and provides a factual account of Mangoceuticals, Inc.’s recent financial activity as disclosed in their latest SEC filing.
In other recent news, Mangoceuticals, Inc. has been actively involved in several significant developments. The company recently announced the conversion of its Series B Convertible Preferred Stock into common stock, with transactions resulting in the exchange of hundreds of preferred shares for common shares. This move is part of a broader strategy to simplify the company’s capital structure. Additionally, Mangoceuticals has made changes to its equity securities and executive compensation arrangements, including amendments to the conversion price of its Series B Convertible Preferred Stock and adjustments to its 2022 Equity Incentive Plan.
Moreover, Mangoceuticals has entered into a consulting agreement with 6330 Investment & Consulting Gmbh to identify strategic partners and potential acquisition opportunities, compensating the firm with 200,000 shares of its restricted common stock. The company is also advancing its research in respiratory illness prevention, particularly focusing on H5N1 and H1N1 viruses through studies conducted by Vipragen Biosciences. These studies have shown promising results, encouraging further research phases.
Furthermore, Mangoceuticals is exploring the application of its antiviral technology in poultry drinking water to prevent avian flu infections, potentially offering a non-pharmaceutical alternative to traditional vaccines. The company’s CEO, Jacob Cohen, has expressed optimism about the technology’s potential benefits for the poultry industry. These recent developments indicate Mangoceuticals’ ongoing efforts to expand its business and explore innovative health solutions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.